Sulfamyl Or Substituted Sulfamyl Containing Patents (Class 544/13)
  • Publication number: 20150065492
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: June 10, 2014
    Publication date: March 5, 2015
    Inventors: Peter Dragovich, Douglas E. Murphy
  • Publication number: 20140031346
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is CR3, and A is and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich
  • Patent number: 8586578
    Abstract: The invention is directed to deuterated 5,6-dihydro-1H-pyridin-2-one compounds of Formula I and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: November 19, 2013
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventor: Stephen E. Webber
  • Patent number: 8546602
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: October 1, 2013
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich, Yuefen Zhou, Lijian Chen, David Kucera, Fritz Blatter, Martin Viertelhaus
  • Publication number: 20130184447
    Abstract: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 18, 2013
    Applicant: SYNTHONICS, INC.
    Inventor: SYNTHONICS, INC.
  • Patent number: 8440639
    Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of dorzolamide marketed under the brand Trusoptâ„¢ and Compound A.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: May 14, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley
  • Publication number: 20120328569
    Abstract: Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: March 2, 2011
    Publication date: December 27, 2012
    Inventors: Casey Cameron McComas, Nigel J. Liverton, Richard Soll, Peng Li, Xuanjia Peng, Hao Wu, Frank Narjes, Joerg Habermann, Uwe Koch, Shilan Liu
  • Publication number: 20120329786
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 27, 2012
    Applicant: Myrexis, Inc.
    Inventors: J. Adam Willardsen, Jeffrey W. Lockman, Brett R. Murphy, Weston R. Judd, In Chul Kim, Se-Ho Kim, Daniel Feodore Zigar, Kraig M. Yager, Tracey C. Fleischer, Ryan T. Terry-Lorenzo, J. Jay Boniface, Daniel P. Parker, Ian A. McAlexander, Matthew Gregory Bursavich, David M. Dastrup
  • Publication number: 20120321590
    Abstract: The invention is directed to amides of bicyclic amine compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: April 5, 2012
    Publication date: December 20, 2012
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Chinh V. Tran, Alan X. Xiang, Douglas E. Murphy
  • Publication number: 20120302744
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 29, 2012
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich, Yuefen Zhou, Lijian Chen, David Kucera, Fritz Blatter, Martin Viertelhaus
  • Publication number: 20120283251
    Abstract: The invention is directed to deuterated 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: October 27, 2010
    Publication date: November 8, 2012
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventor: Stephen E. Webber
  • Patent number: 8236948
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: August 7, 2012
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich
  • Publication number: 20120130068
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 24, 2012
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich
  • Patent number: 8129368
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of formula: wherein R is C1-C6 alkyl or (Aryl)CH2-,and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: March 6, 2012
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Frank Ruebsam, Chinh V Tran, Douglas E. Murphy, Peggy A. Thompson, Peter Dragovich, Stephen E. Webber
  • Publication number: 20110263579
    Abstract: The present invention relates to an improved process for the preparation of Chlorothiazide and pharmaceutically acceptable salts thereof. The present invention relates to novel polymorphs of Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium. The present invention further relates to pharmaceutical compositions comprising Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium and process for preparation thereof.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 27, 2011
    Applicant: USV Limited
    Inventors: Dhananjay Govind Sathe, Kamlesh Digambar Sawant, Tushar Anil Naik, Ashok Omray, Yogendra Madhav Agashe, Pragati Tukaram Patade, Sunil Suresh Jog
  • Publication number: 20110166344
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.
    Type: Application
    Filed: March 8, 2011
    Publication date: July 7, 2011
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich, Yuefen Zhou, Lijian Chen, David Kucera, Fritz Blatter, Martin Viertelhaus
  • Publication number: 20110110890
    Abstract: The embodiments provide compounds of the general Formula I and compound 105S, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 12, 2011
    Applicant: INTERMUNE, INC.
    Inventors: Leonid Beigelman, Guangyi Wang, Brad Buckman, Antitsa Dimitrova Stoycheva
  • Patent number: 7939524
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: May 10, 2011
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich, Yuefen Zhou, Lijian Chen, David Kucera
  • Patent number: 7834009
    Abstract: The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds of Formula I and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus: wherein R6 is X is N, Ring A is a 5- or 6-membered aryl, optionally substituted by 1-3 R8 moieties, n is 2, and R1-R6 and R8 are defined herein.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: November 16, 2010
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: David Ellis, Liansheng Li, Chinh V. Tran, Frank Ruebsam, Yuefen Zhou
  • Publication number: 20100256360
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: June 18, 2010
    Publication date: October 7, 2010
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Publication number: 20100184750
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: January 18, 2010
    Publication date: July 22, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Laura A. Hexamer, Hong Ding, Steven W. Elmore, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Michael D. Wendt
  • Publication number: 20100119481
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 13, 2010
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Frank Ruebsam, Chinh V. Tran, Douglas E. Murphy, Peggy A. Thompson, Peter Dragovich, Stephen E. Webber
  • Publication number: 20100034773
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: April 2, 2008
    Publication date: February 11, 2010
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich, Yuefen Zhou, Lijian Chen, David Kucera, Fritz Blatter, Martin Viertelhaus
  • Patent number: 7582754
    Abstract: The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: September 1, 2009
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Frank Ruebsam, Martin Tran, Peter Dragovich, Liansheng Li, Douglas Eric Murphy, David Kucera, Zhongxiang Sun, Chinh Viet Tran
  • Patent number: 7582626
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I and pharmaceutical compositions containing such compounds that are useful in treating hepatitis C virus infections: wherein Z is X is N or CR9; Y is —(CR4R5)n—; n is 2, 3, 4, or 5; and R1 through R9 are defined herein.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: September 1, 2009
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Yuefen Zhou, Peter Dragovich, Alan X. Xiang
  • Patent number: 7531668
    Abstract: A compound represented by the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y1 represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: May 12, 2009
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Takao Suzuki, Minoru Moriya, Shunji Sakuraba, Sayaka Mizutani, Hisashi Iwaasa, Akio Kanatani
  • Publication number: 20090111798
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: December 12, 2007
    Publication date: April 30, 2009
    Inventors: Chinh V. Tran, Frank Ruebsam, Yuefen Zhou, Peter Dragovich, Alan X. Xiang
  • Publication number: 20090105473
    Abstract: The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: November 6, 2008
    Publication date: April 23, 2009
    Applicant: ANADYS PHARMACEUTICALS, INC.
    Inventors: Stephen E. Webber, Frank Ruebsam, Martin Tran, Peter Dragovich, Liansheng Li, Douglas E. Murphy, David Kucera, Zhongxiang Sun, Chinh V. Tran
  • Publication number: 20090062263
    Abstract: The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: August 27, 2007
    Publication date: March 5, 2009
    Inventors: David Ellis, Liansheng Li, Chinh V. Tran, Frank Ruebsam, Yuefen Zhou
  • Publication number: 20080275032
    Abstract: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 11, 2007
    Publication date: November 6, 2008
    Inventors: Yuefen Zhou, Liansheng Li, Stephen E. Webber, Peter Dragovich, Douglas E. Murphy, Chinh V. Tran, Jingjing Zhao, Frank Ruebsam
  • Publication number: 20080255101
    Abstract: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia.
    Type: Application
    Filed: June 10, 2008
    Publication date: October 16, 2008
    Applicant: NITROMED, INC.
    Inventors: David S. GARVEY, L. Gordon LETTS, Richard A. EARL, Maiko EZAWA, Xinqin FANG, Ricky D. GASTON, Subhash P. KHANAPURE, Chia-En LIN, Ramani R. RANATUNGE, Cheri A. STEVENSON, Shiow-Jyi WEY
  • Patent number: 7235548
    Abstract: The invention provides novel compounds represented by the general formula compound represented by the formula: wherein the bond represented by the broken line may be a single, a double bond or absent; and if the bond is absent, then the nitrogen is substituted with a hydrogen and R2; X represents SO2 or C?O or CH2; Y represents —CH(R4)—, —N(R4)— or —N(R4)—CH2—, O; and the meaning of R2, R3, R4, R5, R6, R7, and R8 are as defined in the application The compounds are useful as positive modulators of the AMPA-receptor.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: June 26, 2007
    Assignee: NeuroSearch A/S
    Inventors: Alex Haaht Gouliaev, Mogens Larsen, Thomas Varming, Claus Mathiesen, Tina Holm Johansen, Jorgen Scheel-Kruger, Gunnar M. Olsen, Elsesbet Ostergaard Nielsen
  • Patent number: 7091200
    Abstract: This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: August 15, 2006
    Assignee: Syntex U.S.A. LLC
    Inventors: Cyrus Kephra Becker, Joan Marie Caroon, Chris Richard Melville, Fernando Padilla, Jürg Roland Pfister, Xiaoming Zhang
  • Patent number: 7025816
    Abstract: An anthraquinone dye represented by the Formula (1), (2) or (3), and an ink jet recording liquid containing a compound represented by the following Formula (1), (2) or (3):
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: April 11, 2006
    Assignee: Konica Minolta Holdings, Inc.
    Inventors: Takatugu Suzuki, Satoru Ikesu, Mari Takahashi
  • Publication number: 20040254371
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: June 10, 2004
    Publication date: December 16, 2004
    Inventors: Patrice Desos, Alex Cordi, Pierre Lestage
  • Patent number: 6656932
    Abstract: Selective MMP-13 inhibitors are benzo thiadiazines of the Formula or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or alkyl; R1 and R3 include hydrogen, alkyl, and aryl, with the proviso that R3 is not (CH2)m biphenyl or (CH2)m substituted biphenyl; X is O or NH, n is 0, 1, or 2. The compounds of Formula I, or a pharmaceutically acceptable salt thereof, is useful for treating diseases mediated by an MMP-13 enzyme, including diseases selected from osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: December 2, 2003
    Assignee: Warner-Lambert Company
    Inventors: Joseph Armand Picard, Michael William Wilson
  • Publication number: 20020156069
    Abstract: Selective MMP-13 inhibitors are benzo thiadiazines of the Formula 1
    Type: Application
    Filed: February 13, 2002
    Publication date: October 24, 2002
    Inventors: Joseph Armand Picard, Michael William Wilson
  • Patent number: 5536723
    Abstract: The invention relates to novel S-nitroso derivatives of ACE inhibitors and to pharmaceutical compositions comprising the S-nitrosothiol derivatives of the invention together with a pharmaceutically acceptable carrier.The invention also relates to methods for treating various pathophysiological conditions including acute myocardial infarction, left ventricular dysfunction without overt heart failure, hypertension, pulmonary hypertension, congestive heart failure, angina pectoris, vascular thrombosis, Raynauds syndrome, scleroderma, toxemia of pregnancy, acute renal failure, diabetic nephropathy, and renal artery stenosis, and to methods of inhibiting ACE and effecting vasodilation comprising administering the S-nitrosothiol derivatives of the ACE inhibitors of the invention to an animal.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: July 16, 1996
    Assignee: Brigham & Women's Hospital
    Inventors: Joseph Loscalzo, John Cooke
  • Patent number: 5214140
    Abstract: Bichromophoric methine and azamethine transfer dyes have the formulaZ.sup.2 --Z.sup.1 --LY.sup.1 --Y.sup.2whereL is a bridge member which does not permit any conjugation of .pi.-electrons between Z.sup.1 and Y.sup.1,Y.sup.1 and Z.sup.1 are each independently of the other aminophenylene, which may be benzofused, or heterocyclyl andY.sup.2 and Z.sup.2 are each independently of the other benzoquinoneiminyl, which may be benzofused, or heterocyclyl.
    Type: Grant
    Filed: March 13, 1992
    Date of Patent: May 25, 1993
    Assignee: BASF Aktiengesellschaft
    Inventors: Volker Bach, Karl-Heinz Etzbach, Ruediger Sens
  • Patent number: 5025001
    Abstract: The invention relates to novel S-nitroso derivatives of ACE inhibitors and to pharmaceutical compositions comprising the S-nitrosothiol derivatives of the invention together with a pharmaceutically acceptable carrier.The invention also relates to methods for treating various pathophysiological conditions including acute myocardial infarction, left ventricular dysfunction without overt heart failure, hypertension, pulmonary hypertension, congestive heart failure, angina pectoris, vascular thrombosis, Raynauds syndrome, scleroderma, toxemia of pregnancy, acute renal failure, diabetic nephropathy, and renal artery stenosis, and to methods of inhibiting ACE and effecting vasodilation comprising administering the S-nitrosothiol derivatives of the ACE inhibitors of the invention to an animal.
    Type: Grant
    Filed: March 24, 1989
    Date of Patent: June 18, 1991
    Assignee: Brigham and Women's Hospital
    Inventors: Joseph Loscalzo, John Cooke
  • Patent number: 4997833
    Abstract: Aryloxy-aminoalkanes useful as antihypertensive agents are described and disclosed.
    Type: Grant
    Filed: July 5, 1989
    Date of Patent: March 5, 1991
    Assignee: Boehringer Ingelheim K G
    Inventors: KoHerbert, Franz Esser, Wolfram Gaida, Wolfgang Hoefke, Georg Speck
  • Patent number: 4916127
    Abstract: There are disclosed certain pyrylium salts and a method of making them. The dyes are useful both medicinally in photodynamic therapy and in photoconductive compositions, photoresist and lithographic compositions or optical recording discs. The salts are mixed seleno- or telluropyrylium compounds having a singlet oxygen quantum efficiency of at least 0.005 when exposed as described at wavelengths between about 650 and 1000 nanometers, and a Lewis base anion.
    Type: Grant
    Filed: October 24, 1988
    Date of Patent: April 10, 1990
    Assignee: Eastman Kodak Company
    Inventor: Michael R. Detty
  • Patent number: 4906635
    Abstract: Methods and pharmaceutical compositions are disclosed for reducing intraocular pressure. The methods and compositions employ an active ingredient which comprises certain benzothiadiazinyl and quinazolinyl substituted carboxyalkyl dipeptides wherein the benzothiadiazinyl or quinazolinyl portions are joined to the dipeptide portions by an aminocarbonyl group.
    Type: Grant
    Filed: July 18, 1988
    Date of Patent: March 6, 1990
    Assignee: Schering Corporation
    Inventors: Bernard R. Neustadt, David R. Andrews, Paul E. McNamara, Robert W. Watkins
  • Patent number: 4888424
    Abstract: Hypotensive activity is exhibited by compounds having the formulas ##STR1##
    Type: Grant
    Filed: February 27, 1984
    Date of Patent: December 19, 1989
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Joseph E. Sundeen, David Floyd, Ving G. Lee
  • Patent number: 4826816
    Abstract: Antihypertensive compounds with angiotensin-converting enzyme inhibitory activity and diuretic activity are disclosed. Such compounds are useful in the treatment of cardiovascular disorders, especially hypertension and congestive heart failure, and are useful in the treatment of glaucoma.
    Type: Grant
    Filed: October 4, 1985
    Date of Patent: May 2, 1989
    Assignee: Schering Corporation
    Inventors: David R. Andrews, Federico C. A. Gaeta
  • Patent number: 4749698
    Abstract: Compounds having the general structure ##STR1## and their pharmaceutically acceptable salts, wherein the substituents are defined herein, which exhibit antihypertensive activity.
    Type: Grant
    Filed: July 8, 1985
    Date of Patent: June 7, 1988
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Edward S. Neiss, John T. Suh, John R. Regan, Jerry W. Skiles, Jeffrey N. Barton, James J. Mencel, Paul Menard
  • Patent number: 4746676
    Abstract: Compounds having the general structure ##STR1## and their pharmaceutically acceptable salts, wherein the substituents are defined herein, which exhibit antihypertensive activity.
    Type: Grant
    Filed: September 12, 1984
    Date of Patent: May 24, 1988
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Edward S. Neiss, John T. Suh, John R. Regan, Jerry W. Skiles, Jeffrey N. Barton, Paul Menard
  • Patent number: 4716161
    Abstract: A phenylpiperazine derivative according to the present invention has the following general formula [I]: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen or alkoxy group having 1 to 3 carbon atoms, orR.sup.1 and R.sup.2 or R.sup.2 and R.sup.3 together with carbon atoms to which they are attached form --O(CH.sub.2).sub.m O-- wherein m is an integer of 1 to 3, oreither R.sup.1 or R.sup.2 is amine residue selected from the group consisting of --NH.sub.2 , --NHSO.sub.2 CH.sub.3, --NHCOCH.sub.3 and --NHCONH.sub.2 and the other is hydrogen or alkoxy group of 1 to 3 carbon atoms and R.sup.3 is hydrogen;R.sup.4 and R.sup.5 are independently hydrogen or alkyl group of 1 to 3 carbon atoms;Y is --CO-- or --SO.sub.2 -- provided that at least one of R.sup.1 and R.sup.2 is not hydrogen when Y is --CO--; andn is an integer of 2 to 4.An acid addition salt of the phenylpiperazine derivative having the general formula [I] is included in the present invention.
    Type: Grant
    Filed: April 3, 1985
    Date of Patent: December 29, 1987
    Assignee: Mitsubishi Chemical Industries Limited
    Inventors: Harukazu Fukami, Ryoji Kikumoto, Kenichiro Nakao, Issei Nitta, Shinya Inoue
  • Patent number: 4713238
    Abstract: The invention relates to the novel water soluble chlorothiazide in a complexed state which is derived from the reaction between and N-Vinyl actam polymer and chlorothiazide in alkaline media and to the process for the preparation of said complex.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: December 15, 1987
    Assignee: GAF Corporation
    Inventor: Eugene S. Barabas
  • Patent number: 4681886
    Abstract: This invention is directed to substituted 4-phenoxy and 4-phenylthio prolines of the formula ##STR1## which possess useful hypotensive activity.
    Type: Grant
    Filed: April 25, 1983
    Date of Patent: July 21, 1987
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Rudiger D. Haugwitz, Peter W. Sprague